Back to search

Switzerland· 68897006

Rivasur due volte alla settimana 9,5 mg/24 ore, cerotto transdermico

A rivastigmine product containing rivastigminum, registered in Switzerland by Zambon Svizzera SA and dispensed under Swissmedic category B, on the national reimbursement list. The same ATC class is registered in 18 of our 19 countries.

Reimbursed in Switzerland (BAG SL)Cat B (Swissmedic)ATC N06DA03

Checked against Swissmedic (Switzerland) on

Informational only — not a medical device.

SOURCE REGISTER · CHSwissmedic (Switzerland)normalisedRivasur due volte alla settimana 9,5 …ATCN06DA03REGISTER NO.68897006PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Rivastigmine is registered in 18 of 19 countries.

Countries holding a registration under ATC N06DA03 (rivastigmine), each read from that country’s own register.

  • This record: Switzerland, from Swissmedic (Switzerland)
  • 11 of them publish a price we can compare per daily dose

Rivastigmine · ATC N06DA03

18 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Spainprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of rivastigmine costs, country by country.

Normalised to the WHO defined daily dose (9 mg), the median price runs from $0.042 in Czechia to $2.19 in Italy — a ×52 gap.

  • Switzerland: $1.33 per daily dose (median across products in the class)
  • Public list prices, converted to USD at the rate date shown

Rivastigmine · price per daily dose (9 mg)

USD · FX 28 Sept 2026

  • IT Italy$2.19
  • CH Switzerland$1.33
  • CZ Czechia$0.042
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

Swissmedic (Switzerland)
Active substance
rivastigminum
Manufacturer
Zambon Svizzera SA
Country
Switzerland (CH)
ATC code
N06DA03
ATC class
Rivastigmine
Defined daily dose
9 mg, O
Swissmedic category
B
Reimbursed
Yes
Source register
Swissmedic (Switzerland)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • gtin
    7680688970067
    8 Stk
    CHF 51.55

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

235 interactions on record for rivastigmine.

Graded by severity as the source publishes them — 8 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Rivastigmine · interactions on record

235 records

  • 8 severe
  • 166 moderate
  • 59 info

Most severe, free to view

  • OzanimodL04AA38severe
  • SiponimodL04AA42severe
  • OzanimodL04AE02severe
  • SiponimodL04AE03severe

2 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Rivastigmine in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All rivastigmine products

Authorised across Europe · EMA

The same active substance is authorised in 22 EEA countries. Names it is sold under:

  • Austria · Nimgista, Rivagelan
  • Belgium · Rivastigmin Sandoz, Rivastigmine Viatris
  • Bulgaria · Ридаксин
  • Germany · Demelora, Rivastigmin
  • Denmark · Rigmin, Rivastigmin Orion
  • Spain · Alzerta, Alzerta Dos Por Semana
  • Finland · Rivastigmin Orion, Rivastigmine Sandoz
  • France · Rivastigmine Arrow, Rivastigmine Biogaran
  • United Kingdom (Northern Ireland) · Almuriva, Alzest
  • Greece · Alapril, Balaxon
  • Iceland · Exelon, Nimvastid
  • Italy · Demelora, Rivastigmina Aurobindo
  • Liechtenstein · Exelon, Rivastigmine 1 A Pharma
  • Malta · Rivastigmine Aurobindo
  • Netherlands · Ristidic, Rivastgimine Neuraxpharm
  • Norway · Exelon, Nimvastid
  • Poland · Atmina, Evertas
  • Portugal · Nervopan, Rivastigmina Alter
  • Romania · Evertas, Ridaxin
  • Sweden · Rigmin, Rivastigmin Orion
  • Slovenia · Rivastigmin Teva, Rivastigmin Teva B.V.
  • Slovakia · Ristidic

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/fdeac15f-f269-4d73-a085-aab8075bdaf6
GET /v1/drugs/fdeac15f-f269-4d73-a085-aab8075bdaf6?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "unit": null,
  "strength": "rivastigminum",
  "valid_from": "2026-08-01",
  "limitations": "[{\"description\":\"<p>Rivasur wird 2-mal pro Woche appliziert.</p>\\n<p><strong>Symptomatische Behandlung von Patienten mit leichter bis mittelschwerer Alzheimer-Krankheit:</strong><br>Zu Therapiebeginn und regelm&auml;ssig im Verlauf der Therapie (alle 6 Monate) ist jeweils im Rahmen der klinischen Gesamtbeurteilung (Alltagsfunktion, Verhaltensauff&auml;lligkeiten, Kognition) eine Beurteilung der Kognition mittels kognitivem Screening vorzunehmen: Durchf&uuml;hrung eines Minimentaltests (mini mental status examination (MMSE), ggf. Umrechnung Montreal Cognitive Assessment (MoCA). Im Stadium schwerer Demenz oder wenn die MMSE-Werte unter 10 liegen, ist die Behandlung zu beenden. Die Behandlung darf nur mit einem Pr&auml;parat zur Behandlung der Alzheimer-Krankheit durchgef&uuml;hrt werden, eine Kombinationsbehandlung wird nicht verg&uuml;tet.</p>\",\"costApproval\":null,\"indication\":\"21686.01\",\"isNew\":true,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2026-08-01\"}]",
  "galenic_form": "TTS 9.5 mg/24h",
  "therapeutic_area": null,
  "sl_inclusion_date": "2026-08-01",
  "self_retention_pct": 10
}

See everything about rivastigmine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.